In recent years, with continuous research efforts targeted at studying the effects of pre-and after-treatment of inhaled anesthetics, significant progress has been made regarding the common clinical use of low concentrations of inhaled sevoflurane and its effect on induced central ischemia tolerance by pre-and post-treatment. In this study, we collected, analyzed, classified, and summarized recent literature regarding the effect of sevoflurane on central ischemia tolerance and its related mechanisms. In addition, we provide a theoretical basis for the clinical application of sevoflurane to protect the central nervous system and other important organs against ischemic injury.
INTRODUCTION
In recent years, the inhaled anesthetic sevoflurane has been widely used for general anesthesia and sedation, especially for the induction and maintenance of general anesthesia in children during surgeries. In addition to its anesthetic properties, pre-and after-treatment with sevoflurane may be useful for the treatment of cerebral ischemic injury and related diseases. Evidence suggests that sevoflurane administration either prior to or after surgery can provide tolerance to ischemia both directly and indirectly, but the effects of pre-and post-treatment and the mechanisms underlying these effects are not exactly the same [1] . In this paper, we review the effect of sevoflurane on central ischemia tolerance and the underlying mechanisms.
THE EFFECT OF SEVOFLURANE PRE-TREATMENT ON ISCHEMIA TOLERANCE
sevoflurane pre-conditioning inhibited microglial activation, alleviated neuronal apoptosis caused by inflammatory reactions, and promoted the recovery of motor function in injured animals [8] . However, the effect of sevoflurane pre-treatment may only be observed in adult animals, as it has been shown that 2% sevoflurane induced hippocampal neuronal apoptosis in rats at puberty, and transiently affected the ability of young rats to form memories in response to noxious stimuli, although it did not cause a decline in spatial memory [9] .
In summary, concentrations of 2% to 4% sevoflurane for pre-treatment for periods of 60 min or less induced tolerance to ischemia in adult rodent models of focal cerebral ischemia, whole brain cerebral ischemia, and spinal cord reperfusion injury.
THE EFFECT OF SEVOFLURANE AFTER-TREATMENT ON ISCHEMIA TOLERANCE
In 2013, Zhu et al. found that sevoflurane aftertreatment had certain protective effects on damaged myocardium [10] . The effect of sevoflurane aftertreatment on ischemic tolerance has received increasing attention and recognition in recent years. Li et al. used the MCAO model to study the effect of sevoflurane inhalation after-treatment on cerebral ischemic tolerance; treatment with 2.6% sevoflurane for 60 min immediately after reperfusion injury significantly reduced neurologic deficit scores, decreased cerebral infarction volume, and resulted in lower levels of oxidative stress, thus exerting a neuroprotective effect [11] . Yu and Jia found that 2.5% It is worth noting that the post-treatment effect of sevoflurane occurs after damage has been induced and before behavioral intervention. Perioperative application of sevoflurane can not only cause a general anesthesia effect but may also produce tolerance to ischemia and achieve the goal of reducing brain injury.
THE EFFECT OF SEVOFLURANE PRE-TREATMENT AND POST-TREATMENT ON MECHANISMS OF ISCHEMIC TOLERANCE
Sevoflurane has been widely used for clinical anesthesia, but the mechanism underlying its effect on ischemic tolerance is still being explored. In recent years, research results have suggested that the mechanisms controlling sevoflurane-induced ischemic tolerance may be related to regulation of cerebral blood flow [17] , inhibition of apoptosis, relief of antioxidant stresses, inhibition of excitatory toxins, activation of mitochondrial ATP-sensitive potassium channels, and stimulation of phosphatidylinositol 3-kinase/protein kinase signaling pathways.
Cerebral blood flow regulation
Research by Bundgaard et al. suggests that in surgical operations to remove brain tumors, inhaled sevoflurane at 1.5% (0.7 MAC) to 2.5% (1.3 MAC) can increase cerebral blood flow and reduce cerebral vascular resistance in a dose-dependent manner [18] . However, Zhang et al. found that sevoflurane post-treatment reduced cerebral blood supply after ischemic damage [19] . Reinsfeh and colleagues believe that sevoflurane affects extracorporeal circulation to regulate cerebral blood flow and metabolism [20] . Due to contradictory reports, there is not yet a consensus on the effect of sevoflurane on cerebral blood flow regulation . Therefore, whether cerebral blood flow changes can explain the cerebral protective effect of sevoflurane is unclear.
Anti-apoptotic mechanisms
Several reports have confirmed that sevoflurane preprocessing or post-treatment has an anti-apoptotic effect.
These studies have focused not only on specific markers of apoptosis and cell morphology analysis, but also on apoptosis pathways and related molecules.
Classical apoptotic pathways include intracellular and extracellular pathways. Intracellular pathways related to cell apoptosis consist of caspase-dependent and caspaseindependent signaling pathways. It has been confirmed that sevoflurane pre-and post-treatment can control caspase 3, as well as the expression of activated caspase 3, leading to the reduction of apoptosis of neurons after cerebral ischemic injury [7] . Li et al. has recently found that sevoflurane pre-processing can inhibit phosphorylation of astrocyte differentiation-related genes, thus inhibiting the expression of activated caspase 3, alleviating neuronal apoptosis, and inducing ischemic tolerance [2] . These experiments on the mechanisms by which sevoflurane pre-processing affects ischemic tolerance provides a new theoretical basis for understanding targets of cerebral ischemia/reperfusion injury.
Closely associated with cell apoptosis are extracellular pathways. These pathways are mainly associated with the Bcl-2 family, in which Bcl-2 is the main anti-apoptotic factor and Bax promotes apoptosis; the balance between pro-apoptotic and anti-apoptotic members regulates apoptosis [21] . After brain injury produces ischemia, the apoptosis protein Bax and anti-apoptotic protein Bcl-2 migrate from the cytoplasm into the mitochondria, where their distribution is consistent with the release of cytochrome C and caspase-9. Thus Bax, mediated by the mitochondrial apoptosis pathway in injured neurons, plays an important role [22] . It is reported that 2.5%
sevoflurane post-treatment has a protective effect against whole cerebral ischemic injury in rats, which is achieved by increasing Bcl-2 protein levels. Post-treatment with sevoflurane combined with albumin can strengthen the effect of sevoflurane on ischemic tolerance [13] . In addition, sevoflurane post-treatment can also increase Bcl-2 protein and mRNA levels, and reduce Bax protein and mRNA expression, thus promoting tolerance to ischemia [23] . Sevoflurane post-treatment can reduce the number of apoptotic cells after cerebral ischemic injury by raising Bcl-2 protein levels and decreasing Bax protein levels, thus inhibiting apoptosis. Preliminary results from our current study show that sevoflurane can reduce the expression of Bax, increase Bcl-2 expression, and diminish electromagnetic pulse radiation-induced mitochondria damage and apoptosis in rat cortical neurons.
This suggests that sevoflurane can regulate the mitochondrial apoptosis pathway mediated by Bax and play a protective role in the CNS [16] .
Anti-oxidant stress mechanisms
After severe injury, the CNS produces large numbers of oxygen free radicals. If these free radicals produced are not completely removed by the body due to their large numbers, it will lead to oxidation, specifically, lipid peroxidation, which may induce serious CNS injury [24] . We have also found in previous reports that sevoflurane post-treatment can inhibit the oxidative stress reaction and decrease the extent of electromagnetic pulse radiation damage in rat cerebral cortex neurons.
Inhibition of excitatory toxin release
It has been confirmed that excitatory amino acids cascading reactions leading to cell death [28] . Zhang et al. confirmed that sevoflurane can reduce glutamate excitatory toxicity [29] , but also questioned the effect of sevoflurane [30] . Therefore, further investigation is required to determine whether sevoflurane exerts a neuroprotective effect by inhibiting excitatory toxin release.
The activation of mitochondrial ATP-sensitive potassium channels
Mitochondrial ATP-sensitive potassium (mitoKATP) channels are present on the inner mitochondrial membrane of many tissues and cells, and play an important role in brain injury. The protective effects of sevoflurane pre-processing are associated with activation of mitoKATP channels, and sevoflurane-induced channel opening promotes ischemic tolerance [31] . Velly et al.
found that early sevoflurane pre-treatment for ischemia/ reperfusion brain protection had a "threshold effect" and was dose-dependent in a clinically relevant concentration range, and that the mechanism was related to opening of mitoKATP channels [32] . Adamczyk reported that whether sevoflurane was administered as pre-treatment or as after-treatment, it played a neuroprotective role by inducing the opening of mitoKATP channels. A recent study has also pointed out that sevoflurane post-treatment can play a protective role in the CNS via mitoKATP channels [33] , which can be reversed by the mitoKATP inhibitor 5-hydroxydecanoic acid [34] . 
Anti-inflammatory effects
The Forty-five rats were randomly assigned to five groups as follows: (1) at an interval of 10 min to achieve post-conditioning. In the celecoxib + sevoflurane group (n = 10), administration of celecoxib 2 mg/kg and the sevoflurane after-treatment were performed simultaneously. Necrotic or apoptotic cells were examined in the hippocampus 7 days after ischemia. Serum levels of proinflammatory cytokines including tumor necrosis factor-α and interleukin-1β were measured 2 h, and 3 and 7 days after ischemia. Necrotic or apoptotic cells were observed more frequently in the control group than in the celecoxib or sevoflurane groups 7 days after ischemia (P < 0.05). Cytokine levels were higher in the control group when compared with the celecoxib or sevoflurane groups 2 h after ischemia (P < 0.05). However, the histological outcomes and cytokine levels were similar in all three groups treated with celecoxib or sevoflurane. It was concluded that combined treatment with celecoxib and sevoflurane after global cerebral ischemia has no additive neuroprotective effects in rats [37] .
CONCLUSION
From the discussion, we can conclude that the protective effects of sevoflurane inhalation against CNS damage have been widely confirmed, although specific mechanisms require further investigation. We believe that further study on the neuroprotective effect of sevoflurane and its underlying mechanism will provide a more thorough theoretical basis for its clinical application.
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